Stem cell transplant shows promise for blinding eye disease
NCT ID NCT02286089
First seen Nov 05, 2025 · Last updated Apr 28, 2026 · Updated 24 times
Summary
This study tests a new treatment called OpRegen for people with advanced dry age-related macular degeneration (geographic atrophy), a leading cause of vision loss. The treatment uses special cells grown from stem cells that are placed under the retina to replace damaged cells. The main goals are to see if the treatment is safe and if it can slow down the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cincinnati Eye Institute
Cincinnati, Ohio, 45242, United States
-
Hadassah Medical Center
Jerusalem, 9112001, Israel
-
Kaplan Medical Center
Rehovot, 76100, Israel
-
Mid Atlantic Retina
Philadelphia, Pennsylvania, 19107, United States
-
Rabin Medical Center
Petah Tikva, 4941492, Israel
-
Tel Aviv Sourasky Medical Center
Tel Aviv, 6423906, Israel
-
West Coast Retina Medical Group
San Francisco, California, 94109, United States
Conditions
Explore the condition pages connected to this study.